DME Competitive Bidding Provisions Could Expose CMS To Litigation – Report
This article was originally published in The Gray Sheet
Executive Summary
White House data quality guidelines expected to be promulgated by Oct. 1 could make CMS vulnerable to legal challenge if DME competitive bidding provisions of the House Medicare bill are enacted, according to a report commissioned by manufacturers
You may also be interested in...
Sen. Cleland Opposes DME Competitive Bidding Practice In Letter To Daschle
The newly formed Coalition for Access to Medical Services, Equipment and Technology (CAMSET) has a congressional ally in Sen. Max Cleland (D-Ga.)
DME Competitive Bidding Demonstration Project Authorized By HR 4954
AdvaMed's support of DME competitive bidding provisions in the House prescription drug benefits package indicates the group's willingness to set aside its concerns with the issue to achieve the larger goal of Medicare inpatient reforms
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.